189 related articles for article (PubMed ID: 37138889)
1. Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics.
Wang Y; Zhang M; Xue Q; Zhou H; Chen J; Wang H; Zhang Y; Shi W
Front Immunol; 2023; 14():1172307. PubMed ID: 37138889
[TBL] [Abstract][Full Text] [Related]
2. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.
Zheng M; Bao Y; Wang J; Ma Y; Yang Y; Zhang P; Chen L; Zheng K; Zhou J
Hematol Oncol; 2022 Aug; 40(3):381-389. PubMed ID: 35405763
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.
Takahashi E; Ohshima K; Kimura H; Hara K; Suzuki R; Kawa K; Eimoto T; Nakamura S;
Histopathology; 2011 Oct; 59(4):660-71. PubMed ID: 22014047
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
Park S; Ko YH
J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
[TBL] [Abstract][Full Text] [Related]
5. Chronic active Epstein-Barr virus infection associated with hemophagocytic syndrome and extra-nodal natural killer/T-cell lymphoma in an 18-year-old girl: A case report.
Xing Y; Yang J; Lian G; Chen S; Chen L; Li F
Medicine (Baltimore); 2017 May; 96(19):e6845. PubMed ID: 28489771
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS; Oon ML; Wang S; Tan SY; Ng SB
Pathology; 2020 Jan; 52(1):111-127. PubMed ID: 31767131
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.
Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS
Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953
[TBL] [Abstract][Full Text] [Related]
9. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
Front Pediatr; 2019; 7():183. PubMed ID: 31231620
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
11. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis.
Ma Y; Zhang P; Bao Y; Luo H; Wang J; Huang L; Zheng M
Front Immunol; 2023; 14():1093719. PubMed ID: 36969150
[TBL] [Abstract][Full Text] [Related]
13. Adult patient with Epstein-Barr virus (EBV)-associated lymphoproliferative disorder: chronic active EBV infection or de novo extranodal natural killer (NK)/T-cell lymphoma, nasal type?
Ohtsuka R; Abe Y; Sada E; Kiyasu J; Ashikari A; Shiratsuchi M; Nishimura J; Takayanagi R; Ohshima K
Intern Med; 2009; 48(6):471-4. PubMed ID: 19293549
[TBL] [Abstract][Full Text] [Related]
14. Extranodal NK/T-cell lymphoma of the nasal cavity developed in a patient with intestinal Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder.
Furuya G; Abe H; Shinozaki-Ushiku A; Yamashita A; Ihara S; Hirata Y; Chiba A; Fujioka Y; Kurokawa M; Koike K; Fukayama M
Pathol Res Pract; 2018 Jul; 214(7):1051-1055. PubMed ID: 29843925
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
[TBL] [Abstract][Full Text] [Related]
16. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
[TBL] [Abstract][Full Text] [Related]
17. [The understanding of Epstein-Barr virus associated lymphoproliferative disorder].
Zhou XG; Zhang YL; Xie JL; Huang YH; Zheng YY; Li WS; Chen H; Liu F; Pan HX; Wei P; Wang Z; Hu YC; Yang KY; Xiao HL; Wu MJ; Yin WH; Mei KY; Chen G; Yan XC; Meng G; Xu G; Li J; Tian SF; Zhu J; Song YQ; Zhang WJ
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):817-821. PubMed ID: 28056294
[TBL] [Abstract][Full Text] [Related]
18. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
19. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications.
Paik JH; Choe JY; Kim H; Lee JO; Kang HJ; Shin HY; Lee DS; Heo DS; Kim CW; Cho KH; Kim TM; Jeon YK
Leuk Lymphoma; 2017 Jan; 58(1):53-63. PubMed ID: 27157296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
